euro adhoc: november AG / Strategic management decisions / november AG´s subsidiary PROGEN Biotechnik GmbH sells key assets to AXIS-SHIELD GmbH

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

Spin-offs

02.03.2009

(Erlangen, March 2, 2009) PROGEN Biotechnik GmbH, a wholly-owned
subsidiary of november AG, has today concluded a contract with
AXIS-SHIELD GmbH, Heidelberg, the Germany subsidiary of the
AXIS-SHIELD-Group, on the sale of key assets belonging to its
Point-of-Care Division. The contract will have retrospective effect
from March 1, 2009. The contract relates to the GlucoTalk blood sugar
measuring device and NycoCard™ and Afinion™, AXIS-SHIELD PoC AS´s
products for diabetics that were to date distributed in Germany,
Austria and Hungary by PROGEN Biotechnik GmbH. It is also planned
that PROGEN Biotechnik GmbH employees who were previously primarily
involved with the products that have now been sold will in future be
employed by AXIS-SHIELD GmbH. The aforementioned areas of activity
represent around 50% of PROGEN Biotechnik GmbH´s current sales
revenues. The purchase price is EUR 1.2 million. For a transitional
period of two months, the parties have agreed a service contract
under which PROGEN Biotechnik GmbH will receive an additional payment
of EUR 200,000.00. Provision has also been made for payments to be
made to PROGEN Biotechnik GmbH for the transfer of inventories.

The asset sale was prompted by AXIS-SHIELD PoC AS´s termination of
the previous sales and distribution contract. PROGEN Biotechnik GmbH
will now re-focus on its core business of development, production and
sale of in-vitro diagnostics and research reagents and expand these
areas of activity.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: november AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Dirk Zurek

CEO

Tel.: +49 (0) 6221 8278-0

E-Mail: ir@november.de

Branche: Biotechnology
ISIN: DE000A0S9N72
WKN: A0S9N7
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade